A Literature Review of Molecular-Targeted Therapies for Epidermal Growth Factor in Advanced Non-Small Cell Lung Cancer
- سال انتشار: 1400
- محل انتشار: پنجمین کنگره بین المللی سرطان
- کد COI اختصاصی: CANCERMED05_008
- زبان مقاله: انگلیسی
- تعداد مشاهده: 476
نویسندگان
Medical Student, Student Research Committee, Faculty of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran
Department of Internal Medicine, Mashhad Medical Sciences Branch, Islamic Azad University, Mashhad, Iran- Solid Tumors Research Center, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Pathology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran
چکیده
Introduction: Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than two-thirds of cases, with the majority of patients (۸۴%) having advanced illness at the time of diagnosis. With snappy improvements in cancer research, the number of possible new treatments is growing. Targeted cancer therapies employ pharmacological substances to slow cancer development, enhance cell death, and prevent spreading. We conducted a literature review to find more novel combination therapies involving immunotherapies or targeted molecular therapies for EGFR in advanced Lung cancer. Methods This review was conducted using keywords such as target therapy, immunotherapy, targeted molecular therapies, and Lung cancer in PubMed, Scopus, Medline, Science Direct, and Web of Science based on Cochrane Highly Sensitive Search Strategy. Results The discovery of targetable mutations (EGFR, ALK, PI۳K/AKT/mTOR, RAS-MAPK, RET, MET, BRAF, and NTRK/ROS۱) in advanced NSCLC patients has changed the therapeutic paradigm. This systematic review showed that Immunotherapy drugs including Aflutinib (ASK۱۲۰۰۶۷), BDTX-۱۸۹, CLN-۰۸۱ (TAS۶۴۱۷), D-۰۳۱۶, Dacomitinib, DZD۹۰۰۸, FCN-۴۱۱, JNJ-۶۱۱۸۶۳۷۲, Nazartinib (EGF۸۱۶), Necitumumab, Osimertinib, Tarloxotinib, WSD۰۹۲۲-FU, and ZN-e۴ (KP-۶۷۳) have the function of EGFR therapy in combination with other targeted agents. Conclusion The discovery of new medicines that target actionable mutations in cancer cells has helped to improve lung cancer mortality during the previous decade. Despite the fact that these medicines have transformed our clinical practice, resistance to them still exists. This literature review showed that targeted molecular therapies could identify escape routes, and employing next-generation medicines alone or in combination can assist us in overcoming this issue.کلیدواژه ها
Advanced NSCLC, Targeted therapy, Immunotherapy, Lung cancerمقالات مرتبط جدید
اطلاعات بیشتر در مورد COI
COI مخفف عبارت CIVILICA Object Identifier به معنی شناسه سیویلیکا برای اسناد است. COI کدی است که مطابق محل انتشار، به مقالات کنفرانسها و ژورنالهای داخل کشور به هنگام نمایه سازی بر روی پایگاه استنادی سیویلیکا اختصاص می یابد.
کد COI به مفهوم کد ملی اسناد نمایه شده در سیویلیکا است و کدی یکتا و ثابت است و به همین دلیل همواره قابلیت استناد و پیگیری دارد.